Biology of Blood and Marrow Transplantation
Volume 15, Issue 1 , Pages 54-60 , January 2009

Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy

  • Carolyn E. Behrendt

      Affiliations

    • Division of Biostatistics and Epidemiology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • Corresponding Author InformationCorrespondence and reprint requests: Carolyn E. Behrendt, PhD, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010.
    • ,
  • Joseph Rosenthal

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • Division of Pediatrics, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • Ellen Bolotin

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • Division of Pediatrics, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • Ryotaro Nakamura

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • John Zaia

      Affiliations

    • Division of Virology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
    • ,
  • Stephen J. Forman

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California

Received 11 September 2008 ,Accepted 23 October 2008.

  • Image Result

    Relapse-free survival, by donor/recipient CMV serostatus (n = 140). Number of subjects at baseline, year 1, year 2, and year 3 were, for D−/R− graft, 35, 16, 8, and 6, and for other grafts, 105, 59, 4

    Relapse-free survival, by donor/recipient CMV serostatus (n = 140). Number of subjects at baseline, year 1, year 2, and year 3 were, for D−/R− graft, 35, 16, 8, and 6, and for other grafts, 105, 59, 44, and 33, respectively.

  • Image Result
    Cumulative incidence of relapse and nonrelapse mortality (NRM), by donor/recipient CMV serostatus (n = 140). Cumulative incidence is indicated using solid lines for relapse, dashed lines for NRM. Gray

    Cumulative incidence of relapse and nonrelapse mortality (NRM), by donor/recipient CMV serostatus (n = 140). Cumulative incidence is indicated using solid lines for relapse, dashed lines for NRM. Gray color corresponds to D−/R− graft, black to other grafts.

 Financial disclosure: See Acknowledgments on page 59.

PII: S1083-8791(08)00472-2

doi: 10.1016/j.bbmt.2008.10.023

Biology of Blood and Marrow Transplantation
Volume 15, Issue 1 , Pages 54-60 , January 2009

Article Tools

* Image Usage & Resolution